Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS) by Quercioli, Alessandra et al.
REVIEW
Inflammation accelerates atherosclerotic processes
in obstructive sleep apnea syndrome (OSAS)
Alessandra Quercioli & François Mach &
Fabrizio Montecucco
Received: 9 November 2009 /Revised: 26 January 2010 /Accepted: 31 January 2010 /Published online: 3 March 2010
# Springer-Verlag 2010
Abstract Obstructive sleep apnea syndrome (OSAS) is an
often underestimated sleep disorder that has been associated
with cardiovascular disease. OSAS is characterized by
cycles of apnea and/or hypopnea during sleep caused by
the collapse of the upper airways. Intermittent hypoxia
deriving from the cycles of apnea/arousals (to retrieve the
ventilation) plays a pivotal role in the pathogenesis of the
disease. Obesity is the most frequent predisposing condition
of OSAS. Recent evidence suggests that OSAS could be
considered as a pro-atherosclerotic disease, independently
of visceral fat amount. Oxidative stress, cardiovascular
inflammation, endothelial dysfunction, and metabolic ab-
normalities in OSAS could accelerate atherogenesis. The
present review is focused on the possible pathophysiolog-
ical mediators which could favor atherosclerosis in OSAS.
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Introduction
Sleep apnea is an underdiagnosed syndrome, characterized
by periods of breathing apnea and/or a marked reduction of
the tidal volume (hypopnea) occurring during sleep.
Obstructive sleep apnea syndrome (OSAS) is caused by
the collapse of the upper airways. OSAS patients manifest
excessive daytime sleepiness related to the fragmentation of
the sleep by frequent arousal, which might favor the
development of cognitive dysfunction and memory loss
because of cerebral hypoxemia [1, 2]. Although it is still
considered as a local and upper airway disorder, OSAS is
now deemed a systemic disease that could involve not only
the respiratory but also central nervous and cardiovascular
systems. Intermittent hypoxemia (IH, intermittent periods
of oxygen saturation below 90%) can increase oxidative
stress, pro-inflammatory cytokine production, platelet ag-
gregation, and metabolic dysregulation [1, 3–5]. Impor-
tantly, sleep-related IH was independently associated with
all-cause mortality in 6,441 men and women participating
in the Sleep Heart Health Study [6]. Several studies have
demonstrated the association of OSAS with arterial hyper-
tension [7, 8], stroke [9–12], coronary artery disease (CAD)
[13–16], or pulmonary hypertension [17]. Sleep-disordered
breathing was also significantly associated with coronary
artery disease-related mortality [6]. The high mortality risk
in untreated sleep-disordered breathing has been shown as
independent of age, sex, and body mass index (BMI) [18].
Thus, recent evidence showed that OSAS should be
considered as a condition predisposing cardiovascular
disease [2, 15, 19–21]. Nevertheless, the elevated incidence
of OSAS in the adult population (4% men and 2% women
between 30 and 60 years of age manifest the severe form of
the disorder, while these percentages go up to 5–15%
considering all stages of the disease) [22–24] and the risk of
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severe systemic complications confer to the diagnosis and
treatment of OSAS a remarkable social importance.
OSAS-associated cardiovascular inflammation and its
clinical relevance will be discussed in the present article.
Clinical relevance of OSAS
OSAS represents a systemic worldwide disease, mainly
affecting obese subjects (up to 70% of OSAS patients are
obese). This association renders difficult to define OSAS
impact as an independent factor of risk [25, 26].
Subjects with OSAS have an increased comorbidity
(CAD, stroke, arterial hypertension) and mortality, while
continuous positive airway pressure (CPAP) treatment
seems to improve survival [27, 28]. Marshall and co-
workers recently showed that moderate to severe OSAS is
independently associated with an increased risk of all-cause
mortality in 397 residents of Busselton town (Western
Australia) after up to a 14-year follow-up [29]. Doherty and
co-workers observed that deaths for cardiovascular disease
were more common in the untreated group of patients than
in the CPAP-treated one during follow-up (14.8% vs. 1.9%,
respectively) [30]. Cross-sectional associations from the
Sleep Heart Health Study cohort (6,424 subjects) demon-
strated that OSAS induces only modest to moderate effects
on cardiovascular disease [15]. On the other hand, OSAS
has high incidence among persons with known CAD (30–
58%) [31, 32]. The relative risk for myocardial infarction in
OSAS subjects for the upper quartile of the apnea index has
been shown to be 23.3 compared with the lowest quartile,
indicating a strong association between OSAS and the acute
coronary syndrome. These studies suggest that OSAS is an
independent risk factor for CAD [14]. Subjects with
coexistent OSAS and CAD have higher mortality (38%
vs. 9%), increased rate of restenose after percutaneous
coronary intervention (24% vs. 5%), and increased rate of
major adverse cardiac events (37% vs. 15%) as compared
to CAD patients without OSAS [33]. Recent studies have
shown early atherosclerotic lesions in OSAS subjects (such
as the increase of intima–media thickness [IMT]), which
can be reduced by CPAP treatment [34–36]. Furthermore,
IMT is significantly correlated to levels of C-reactive
protein (CRP), interleukin (IL)-6, and severity of OSAS
[35]. OSAS is also associated with other signs of early
atherosclerosis, such as increased arterial stiffness and heart
remodeling (increased left atrial diameter, interventricular
septal thickness, and left ventricle mass index), indepen-
dently of other confounding factors [34, 37].
In the last decades, increasing evidence showed that
OSAS is also associated with arterial hypertension [8,
38–40]. Large clinical studies have demonstrated that
OSAS is an independent risk factor for hypertension [7,
20, 41] with an adjusted odds ratio for baseline hyperten-
sion, non-modifiable risk factors, obesity, and smoke of 2.9
[20]. Several studies have also demonstrated that CPAP
treatment not only reduces nocturnal blood pressure [42]
but also decreases daytime diastolic blood pressure [43–45].
On the other hand, some authors failed to find any
beneficial effect on blood pressure when investigating
hypertensive OSAS patients [46].
OSAS has been also related to an increased risk of stroke.
The Sleep Heart Health Study showed a small but significant
increase in stroke prevalence among OSAS subjects [15].
Yaggi and co-workers showed that OSAS subjects have a 2-
fold increased risk of stroke as compared with non-OSAS
subjects in a 3.5-year follow-up [12]. Moreover, OSAS is
associated with a more serious prognosis after stroke [11, 47].
Other known cardiovascular complications are different
types of arrhythmias (brady- and tachyarrhythmias) [48,
49], pulmonary hypertension [50–52], and congestive heart
failure [53, 54].
The nasal CPAP is the gold-standard treatment; it
significantly improves oxygen saturation and general
symptoms. In spite of the existing debate, some studies
have shown that CPAP reduces the levels of systemic
inflammatory markers such as TNF-α, IL-6, CRP, and IL-
8 [55–58].
Several pathogenetic mechanisms have been proposed to
explain the possible association between OSAS and
cardiovascular disease.
Cardiovascular inflammation in OSAS
Oxidative stress
IH is a key element in the pathophysiology of OSAS and its
complications. It consists of cycles of short periods of
oxygen desaturation followed by retrieval of the ventilation
with normalized oxygenation. It has been postulated that IH
is a harmful mechanism analogous to ischemia–reperfusion
injury. In ischemia–reperfusion injury, the damage occurs
when the blood flow to an ischemic or hypoxic tissue is
restored [1, 3, 5, 59, 60] and overproduction of reactive
oxygen species (ROS) is induced. The same mechanism
might be implicated in intermittent hypoxia during sleep.
During reperfusion, ROS are generated through the xanthine
oxidase pathway, the NADPH oxidase pathway, and the
incomplete oxidative phosphorylation in the mitochondria
[22, 61–63]. Accordingly, several oxidative stress markers
are increased in OSAS [62, 64–68] and are reduced after
CPAP treatment [69, 70]. An increased level of ROS, such
as superoxide anion (O2
−), hydroxyl radical (OH−), and
peroxynitrite (ONOO−), provides cell membrane damage
by lipid peroxidation, protein oxidation, depletion of
262 Sleep Breath (2010) 14:261–269
intracellular adenosine triphosphate, alteration in calcium
homeostasis, cellular apoptosis, and oxidative DNA damage.
These events finally could increase endothelial dysfunction
and inflammation [60, 62, 71].
ROS production is associated with the upregulation of
different genes regulated by the pro-inflammatory nuclear
factor kappa B (NF-κB) pathway [3, 72, 73]. NF-κB
mediates the production of inducible NO synthase (iNOS)
[74] and cyclooxygenase (COX)-2. NF-κB also activates
the overexpression of adhesion molecules involved in
leukocyte recruitment and migration to the inflammatory
site, i.e., intercellular adhesion molecule-1 (ICAM-1), E-
selectin, and vascular cell adhesion molecule-1 (VCAM-1)
[73, 75, 76]. Accordingly, NF-κB is highly activated in
OSAS patients as compared to healthy controls. Further-
more, CPAP treatment strongly reduces NF-κB activation
[77]. Interestingly, IH does not seem to activate protective
hypoxia-inducible factor-1 (HIF-1), a key regulator of the
adaptive pathway to chronic hypoxia [72, 78]. The short
duration of hypoxia in IH does not allow the stabilization
of HIF-1 and the cyclic re-oxygenation induces mitochon-
dria dysfunction. Thus, it results in the activation of the
NF-κB pathway alone [78, 79]. These results are contro-
versial and need further confirmations. Indeed, it is well
known that HIF-1 downstream proteins, such as the
vascular endothelial growth factor (VEGF, which regu-
lates the oxygen homeostasis), iNOS, and endothelin-1 (a
potent vasoconstrictor), are increased in OSAS, suggesting
a possible activation of HIF-1 pathway [80–87].
Systemic inflammatory mediators
Several evidences suggest that OSAS might be considered
as a systemic inflammatory disease (Table 1). The levels of
the pro-inflammatory cytokine TNF-α are correlated with the
severity of OSAS. TNF-α modulates physiological sleep [88]
Table 1 Clinical studies investigating the association between inflammatory cardiovascular risk markers and OSAS
Author Year Number of patients Marker Effect
Vgontzas et al. [91] 2000 14 OSAS; 11 obese; 12 controls TNF-α and
IL-6
Increased TNF-α and IL-6 in OSAS vs. controls
Minoguchi et al. [56] 2004 24 OSAS; 15 obese; 12 controls TNF-α Increased TNF-α serum levels in severe
OSAS vs. controls and vs. mild OSAS
Ryan et al. [28] 2006 67 OSAS male; 30 controls male TNF-α and
IL-8
Increased TNF-α and IL-8 in OSAS vs. controls
Yokoe et al. [58] 2003 30 OSAS; 14 obese IL-6 Increased IL-6 in OSAS vs. obese
Al Lawati et al. [99] 2009 176 OSAS (80.1% AHI≥5 events/h and
25% AHI≥30 events/h)
IL-6 No correlation between IL-6 and OSAS severity
Minoguchi et al. [35] 2005 36 OSAS; 16 obese IL-6 and CRP Increase IL-6 and CRP in OSAS vs. obese
Can et al. [102] 2006 62 OSAS male (30 subjects with AHI>5
[group 1] and 32 subjects with AHI<5
[group 2]); 30 controls
CRP and
homocysteine
Increased CRP and homocysteine in OSAS
group 1 vs. group 2. Increased CRP and
homocysteine in OSAS groups vs. control
Taheri et al. [115] 2007 907 OSAS (68.7% AHI<5;
19:1%5  AHI15;
12.2% AHI≥15)
CRP Positive association between CRP and the AHI
(AHI 5–15, AHI≥15). No significant
association
after adjustment for age, sex, and BMI
Kapsimalis et al.
[110]
2008 52 OSAS (26 severe; 26
mild–moderate); 15 non-OSAS
CRP and leptin Increased CRP in severe OSAS vs. non-OSAS.
Increased leptin in severe OSAS and moderate
OSAS vs. non-OSAS
Hayashi et al. [103] 2006 60 OSAS; 30 controls CRP and
MCP-1
Increased CRP and MCP-1 in OSAS vs. control
Ohga et al. [117] 2003 20 OSAS male; 10 control male MCP-1 Increased MCP-1 in OSAS vs. controls
Ip et al. [133] 2000 30 OSAS; 30 non-OSAS matched for BMI,
age, sex, and menopausal status
Leptin Increased leptin in OSAS subjects vs. controls
Phillips et al. [129] 2000 32 OSAS vs. 32 obese Leptin Increased leptin in OSAS vs. controls
Schafer et al. [134] 2002 55 OSAS (8 patients with 10AHI15; 4 patients
with 15AHI20; 22 patients with 20AHI40;
21 patients with AHI>40); 26 controls
Leptin Leptin levels correlate with AHI (r=0.39,
p<0.0003). No significant correlation (r=0.25)
after adjustment for body fat content
Kuramoto et al. [121] 2008 35 patients with 20  AHI40, 46 patients
with AHI≥40, 35 non-OSAS (AHI<20).
SAA Increased SAA in AHI>40 group vs.
AHI<20 group
Tazaki et al. [120] 2004 44 OSAS; 18 controls MMP-9 Increased MMP-9 in OSAS vs. controls
TNF-α tumor necrosis factor-alpha, AHI apnea–hypopnea index, CRP C-reactive protein, MCP-1 monocyte chemoattractant protein-1, BMI body
mass index, SAA serum amyloid A, MMP-9 matrix metalloproteinase-9
Sleep Breath (2010) 14:261–269 263
and is produced by monocytes and T cells through a
transcriptional pathway involving NF-κB and up-regulates
VCAM-1, E- and L-selectin, and ICAM-1 expression. TNF-
α is involved in the increase of NREM sleep [89] and
induces somnolence and fatigue [90]. Accordingly, its levels
are significantly higher in OSAS patients as compared to
healthy controls and lower after treatment with CPAP,
independently of obesity [56, 57, 90–92]. Moreover, in
OSAS subjects, the nocturnal peak of secretion of TNF-α is
replaced by an abnormal daytime peak, thus altering the
secretion rhythm of TNF-α [93]. As these alterations persist
after a 3-month treatment with CPAP, it is likely that they
require much more time to regress. TNF-α might cause the
apneic events by promoting the dysfunction of the upper
airway muscles [59]. On the other hand, interleukin (IL)-6 is
also produced by the adipose tissue and circulating mono-
cytes through the NF-κB pathway during nocturnal hypoxia
[58, 94]. IL-6 represents a major stimulant of CRP
production in the liver [95] and might modulate inflamma-
tory processes in sleep disorders. Differently from TNF-α,
IL-6 circadian rhythm is not altered in OSAS [93]. Although
elevated levels of IL-6 has been shown in OSAS subjects as
compared to healthy controls and a significant improvement
after CPAP treatment [35, 58, 90, 91, 96], other studies did
not confirm the potential role of this cytokine (mainly after
covariate analysis and adjustment for BMI) probably because
of a less severe OSAS included in the studies (mean apnea–
hypopnea index, AHI=22.8/h) [57, 97–99]. Nevertheless,
Zhang and co-workers have recently showed that genetic
variants of the IL-6 gene confer different susceptibility to
develop OSAS, thus suggesting a potential approach to
assess the risk for OSAS [100].
The alteration of CRP levels in OSAS obese patients
remains controversial, mainly because of the relationship
between CRP and BMI [101]. Nevertheless, studies showed
that in OSAS subjects, CRP levels are independently
associated with the severity of the disease [35, 55, 58, 69,
102–108]. Importantly, 1-month treatment with CPAP
significantly reduces CRP levels. More recently, increased
levels of CRP were associated with OSAS in obese men
independently of adiposity [109]. CRP levels also correlate
with the degree of nocturnal hypoxemia independently
of obesity [110]. Larkin and co-workers recently showed
that an AHI ≥5 is associated with increased CRP serum
levels in adolescents without known cardiovascular dis-
eases. The relationship between CRP and sleep-disordered
breathing was also confirmed after adjustment of impor-
tant covariates (including BMI, hypertension, waist-to-hip
ratio, and lipid profile) [104]. Conversely, these interesting
associations were not confirmed by other studies [96, 111–
116]. Larger and controlled studies are needed to better
understand the role of CRP-mediated effects in the OSAS
pathophysiology.
Elevated levels of IL-8 and monocytes chemoattractant
protein (MCP)-1 have been shown in patients with OSAS
[57, 76, 114, 117]. IL-8 is also reduced by 6-week treatment
with CPAP [57]. Chemokines might play a pivotal role in
the pathogenesis of the cardiovascular complications of
OSAS through their crucial activation of neutrophils and
monocytes [118, 119]. In particular, increased serum levels
of leukocyte proteases (such as matrix metalloproteinase
[MMP]-9) have been found in OSAS [120].
A relationship between the acute phase reactant serum
amyloid A (SAA) and the degree of OSAS has been also
shown. Furthermore, SAA levels have been reduced by
CPAP treatment [121].
Leptin is the product of the obese gene in the adipocytes
and mediates several functions such as the regulation of
food intake, the energy balance, and the regulation of lipid
and glucose metabolism [122, 123]. In obesity (a condition
known as leptin resistance), leptin levels are increased [124,
125]. Leptin activates inflammation and mediates cellular
damage synergistically with IH in a rabbit model of OSAS
[78]. Although the major inducing factor for leptin
production is visceral obesity [112], hypoxia might increase
leptin production [126–128]. Furthermore, leptin correlates
with OSAS independently of obesity [129–133]. Kapsimalis
and co-workers confirmed that nocturnal hypoxemia is
associated with leptin independently of obesity [112].
Conversely, other studies did not show a significant
association between leptin levels and OSAS after adjustment
for obesity [134–137].
Homocysteine is a product of the metabolism of the
aminoacid methionine and increases the risk of arterial
occlusive disease [138] causing endothelial dysfunction [3,
139–141]. Controversial data have been reported on
homocysteine levels in OSAS. Some studies indicate that
homocysteine is increased in OSAS subjects with cardio-
vascular disease (CAD) in comparison with OSAS subjects
without CAD and with healthy controls [102, 142].
Accordingly, CPAP treatment reduces homocysteine con-
centrations [143]. Conversely, other studies did not confirm
this association [62, 144]. Finally, studies on insulin [110,
145–147] and adiponectin [132, 147–150] also showed
controversial results. Further studies are needed to better
address the role of these inflammatory cardiovascular risk
markers in OSAS.
Endothelial dysfunction
Endothelium regulates the vascular tone and maintains the
pro-/anti-inflammatory equilibrium in the vessel wall.
Alterations of the normal homeostasis of the vascular wall
represent early signs of cardiovascular diseases [151].
Recent studies have demonstrated that OSAS significantly
affects the endothelial function. Indeed, endothelium-
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dependent vasodilation in response to acetylcholine is
reduced in OSAS patients in comparison with age- and
BMI-matched healthy subjects [152, 153]. Flow-mediated
vasodilation is impaired in OSAS with a direct correlation
with the severity of the hypoxemia [154]. The normal
function of the endothelium depends on the bioavailability
of NO. In OSAS, reduced levels of circulating NO [155,
156] and elevated concentrations of endothelial NO
synthase inhibitor have been shown, as compared to healthy
controls [157].
The mechanisms by which OSAS might affect the
endothelial function are dependent on IH and sleep
fragmentation [158]. As mentioned above, IH causes a
reduction of NO production by affecting the transcriptional
and post-transcriptional pathways and by increasing the
production of ROS. ROS could react with NO, further
reducing its availability and enhance the oxidative stress.
Moreover, IH up-regulates cyclooxygenase-2 (COX-2),
VEGF, endothelin-1, and iNOS, which might further alter
the functional integrity of the endothelium [80–87]. Sleep
fragmentation is associated with 50% reduction of the flow-
mediated vasodilation [159]. Several studies show in-
creased inflammation, activation of the sympathetic tone,
and hypercoagulability during repetitive arousals from
sleep during OSAS [160–162]. Accordingly, treatment with
CPAP reverses endothelial dysfunction [163].
Endothelial dysfunction could be a key element in
atheroprogression in OSAS. Further efforts should be done
in order to better understand and possibly prevent endothe-
lial dysfunction in OSAS.
Conclusions
Despite its underestimation, OSAS should be considered a
serious disease involving not only the respiratory system
but also having cardiovascular and cerebral implications.
The promotion of atherogenesis through oxidative stress,
inflammation, and endothelial dysfunction is still a matter
of debate. Intermittent hypoxia is the distinctive element of
OSAS and could play a pivotal role in triggering cardio-
vascular inflammation. The treatment with CPAP represents
a very promising therapeutic strategy to clinically improve
OSAS and reduce the associated oxidative stress, cardio-
vascular inflammation, and endothelial dysfunction. Larger
randomized clinical studies are still needed to identify more
selective cardiovascular risk markers in OSAS.
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